MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on Humana Value Rx Plan (S5884-218)

Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), New York
Premium
$158.90/month
Deductible
$601.00, doesn't apply to tier 1 and 2
Change plan

5 of 9 IL-17 and IL-23 biologics are covered on this plan. All 5 require prior authorization.

4 aren't on the formulary, including Wezlana and Selarsdi.

  • Stelara
    ustekinumab
    Covered · prior auth
    from $1,260.74
    Tier 5
  • ustekinumab biosimilars
    Wezlana, Selarsdi, Pyzchiva and others
    Covered · prior auth
    from $1,023.17
    Tier 5
  • Skyrizi
    risankizumab
    Covered · prior auth
    from $2,456.31
    Tier 5
  • Tremfya
    guselkumab
    Covered · prior auth
    from $3,785.83
    Tier 5
  • Cosentyx
    secukinumab
    Covered · prior auth
    from $4,245.74
    Tier 5
Not on the formulary
Wezlana, Selarsdi, Taltz, Bimzelx

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $601.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list